187 related articles for article (PubMed ID: 30464532)
1. EZH2 contributes to 5-FU resistance in gastric cancer by epigenetically suppressing FBXO32 expression.
Wang C; Li X; Zhang J; Ge Z; Chen H; Hu J
Onco Targets Ther; 2018; 11():7853-7864. PubMed ID: 30464532
[TBL] [Abstract][Full Text] [Related]
2. EZH2 Contributes To Cisplatin Resistance In Breast Cancer By Epigenetically Suppressing miR-381 Expression.
Dou D; Ge X; Wang X; Xu X; Zhang Z; Seng J; Cao Z; Gu Y; Han M
Onco Targets Ther; 2019; 12():9627-9637. PubMed ID: 32009798
[TBL] [Abstract][Full Text] [Related]
3. TUG1 confers cisplatin resistance in esophageal squamous cell carcinoma by epigenetically suppressing PDCD4 expression via EZH2.
Xu C; Guo Y; Liu H; Chen G; Yan Y; Liu T
Cell Biosci; 2018; 8():61. PubMed ID: 30519392
[TBL] [Abstract][Full Text] [Related]
4. TUG1 confers Adriamycin resistance in acute myeloid leukemia by epigenetically suppressing miR-34a expression via EZH2.
Li Q; Song W; Wang J
Biomed Pharmacother; 2019 Jan; 109():1793-1801. PubMed ID: 30551433
[TBL] [Abstract][Full Text] [Related]
5. PCAT-1 contributes to cisplatin resistance in gastric cancer through epigenetically silencing PTEN via recruiting EZH2.
Li H; Ma X; Yang D; Suo Z; Dai R; Liu C
J Cell Biochem; 2020 Feb; 121(2):1353-1361. PubMed ID: 31478258
[TBL] [Abstract][Full Text] [Related]
6. The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx).
Ciarapica R; De Salvo M; Carcarino E; Bracaglia G; Adesso L; Leoncini PP; Dall'Agnese A; Walters ZS; Verginelli F; De Sio L; Boldrini R; Inserra A; Bisogno G; Rosolen A; Alaggio R; Ferrari A; Collini P; Locatelli M; Stifani S; Screpanti I; Rutella S; Yu Q; Marquez VE; Shipley J; Valente S; Mai A; Miele L; Puri PL; Locatelli F; Palacios D; Rota R
Oncogene; 2014 Aug; 33(32):4173-84. PubMed ID: 24213577
[TBL] [Abstract][Full Text] [Related]
7. EZH2 Contributes to 5-FU Resistance in Gastric Cancer by Epigenetically Suppressing FBXO32 Expression [Retraction].
Onco Targets Ther; 2023; 16():673-674. PubMed ID: 37551312
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of PLA2G2A sensitizes gastric cancer cells to 5-FU in vitro.
Chen D; Jiao XL; Liu ZK; Zhang MS; Niu M
Eur Rev Med Pharmacol Sci; 2013 Jul; 17(13):1703-8. PubMed ID: 23852891
[TBL] [Abstract][Full Text] [Related]
9. MeCP2 confers 5-fluorouracil resistance in gastric cancer via upregulating the NOX4/PKM2 pathway.
Qin Y; Ma X; Guo C; Cai S; Ma H; Zhao L
Cancer Cell Int; 2022 Feb; 22(1):86. PubMed ID: 35180871
[TBL] [Abstract][Full Text] [Related]
10. HOXA13, Negatively Regulated by miR-139-5p, Decreases the Sensitivity of Gastric Cancer to 5-Fluorouracil Possibly by Targeting ABCC4.
Chen Z; Qin Z; Li L; Wo Q; Chen X
Front Oncol; 2021; 11():645979. PubMed ID: 34094932
[TBL] [Abstract][Full Text] [Related]
11. Long noncoding RNA SNHG6 silencing sensitized esophageal cancer cells to 5-FU via EZH2/STAT pathway.
Tan R; Liu J; Wang J; Zhang W; He M; Zhang Y
Sci Rep; 2023 Apr; 13(1):5363. PubMed ID: 37005451
[TBL] [Abstract][Full Text] [Related]
12. LncRNA UCA1 promotes cisplatin resistance in gastric cancer via recruiting EZH2 and activating PI3K/AKT pathway.
Dai Q; Zhang T; Pan J; Li C
J Cancer; 2020; 11(13):3882-3892. PubMed ID: 32328192
[No Abstract] [Full Text] [Related]
13. Silenced PITX1 promotes chemotherapeutic resistance to 5-fluorocytosine and cisplatin in gastric cancer cells.
Shen X; Gu Y; Yu S; Gong P; Mao Y; Li Y; Zheng Y; Qiao F; Zhao Z; Fan H
Exp Ther Med; 2019 May; 17(5):4046-4054. PubMed ID: 31007741
[TBL] [Abstract][Full Text] [Related]
14. Sensitization of Gastric Cancer Cells to 5-FU by MicroRNA-204 Through Targeting the TGFBR2-Mediated Epithelial to Mesenchymal Transition.
Li LQ; Pan D; Chen Q; Zhang SW; Xie DY; Zheng XL; Chen H
Cell Physiol Biochem; 2018; 47(4):1533-1545. PubMed ID: 29940566
[TBL] [Abstract][Full Text] [Related]
15. MiR-195 reverses 5-FU resistance through targeting HMGA1 in gastric cancer cells.
Wang CQ
Eur Rev Med Pharmacol Sci; 2019 May; 23(9):3771-3778. PubMed ID: 31115003
[TBL] [Abstract][Full Text] [Related]
16. LncRNA GAS5 facilitates nasopharyngeal carcinoma progression through epigenetically silencing PTEN
Zhao D; Li Y; Yu M
RSC Adv; 2019 Oct; 9(54):31691-31698. PubMed ID: 35527982
[TBL] [Abstract][Full Text] [Related]
17. Enhancer of zeste homolog 2 exerts functions in gastric cancer development via modulating microRNA-222-3p methylation and WEE1 expression.
Feng Y; Wang C; Shi T; Liu W; Liu H; Zhu B; Gao F
Chem Biol Drug Des; 2022 Sep; 100(3):320-333. PubMed ID: 35765903
[TBL] [Abstract][Full Text] [Related]
18. Silencing the EZH2 gene by RNA interference reverses the drug resistance of human hepatic multidrug-resistant cancer cells to 5-Fu.
Zhang Y; Liu G; Lin C; Liao G; Tang B
Life Sci; 2013 May; 92(17-19):896-902. PubMed ID: 23562851
[TBL] [Abstract][Full Text] [Related]
19. TWEAK/Fn14 signaling mediates gastric cancer cell resistance to 5-fluorouracil via NF-κB activation.
Kwon OH; Kim JH; Kim SY; Kim YS
Int J Oncol; 2014 Feb; 44(2):583-90. PubMed ID: 24337061
[TBL] [Abstract][Full Text] [Related]
20. STAT3 signaling drives EZH2 transcriptional activation and mediates poor prognosis in gastric cancer.
Pan YM; Wang CG; Zhu M; Xing R; Cui JT; Li WM; Yu DD; Wang SB; Zhu W; Ye YJ; Wu Y; Wang S; Lu YY
Mol Cancer; 2016 Dec; 15(1):79. PubMed ID: 27938379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
